Advances in primary glomerulonephritis.
Ellison B, Cader R, Willcocks L.
Br J Hosp Med (Lond). 2024 Jul 30;85(7):1-11. doi: 10.12968/hmed.2024.0044.
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J.
Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015.
Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial.
Medjeral-Thomas NR, Lawrence C, Condon M, Sood B, Warwicker P, Brown H, Pattison J, Bhandari S, Barratt J, Turner N, Cook HT, Levy JB, Lightstone L, Pusey C, Galliford J, Cairns TD, Griffith M.
Clin J Am Soc Nephrol. 2020 Feb 7;15(2):209-218. doi: 10.2215/CJN.06180519. Epub 2020 Jan 17.
Minimal change nephropathy and graves' disease: report of a case and review of the literature.
Tanwani LK, Lohano V, Broadstone VL, Mokshagundam SP.
Endocr Pract. 2002 Jan-Feb;8(1):40-3. doi: 10.4158/EP.8.1.40.
Diabetic nephropathy with minimal change disease: a case report.
Miao P, Mo X, Zhang X, Zhang M.
Front Endocrinol (Lausanne). 2025 Jul 18;16:1623272. doi: 10.3389/fendo.2025.1623272. eCollection 2025.
IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?
Brugnano R, Del Sordo R, Covarelli C, Gnappi E, Pasquali S.
J Nephrol. 2016 Aug;29(4):479-86. doi: 10.1007/s40620-016-0269-6. Epub 2016 Feb 3.
Post-vaccinal minimal change disease.
Weijers J, Alvarez C, Hermans MMH.
Kidney Int. 2021 Aug;100(2):459-461. doi: 10.1016/j.kint.2021.06.004. Epub 2021 Jun 10.
Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility.
Roman M, Nowicki M.
Int J Mol Sci. 2024 Nov 13;25(22):12174. doi: 10.3390/ijms252212174.
Telitacicept for minimal change disease.
Li S, Ding L, Yang YJ, Yang XD.
Kaohsiung J Med Sci. 2023 Jul;39(7):748-749. doi: 10.1002/kjm2.12719.
The diagnosis of minimal change disease in diabetic nephropathy.
Stokes MB.
ScientificWorldJournal. 2005 Sep 29;5:828-33. doi: 10.1100/tsw.2005.106.
